IP Library Granted Patent US 9,101,570
Granted Patent B1
US 9,101,570 · App. 12/697,537 · Granted Aug 11, 2015

Adult and neonatal stem cell therapy to treat diabetes through the repair of the gastrointestinal tract

Inventors: Neil F. Duffy, Jr. (Brighton, MA); Andrew McGillicuddy (Hanover, MA)
Assignee: EndoCellutions, Inc.
A61K35/12A61K35/28A61K35/35A61K35/50C12N5/06C12N5/0607C12N5/0653C12N5/0663C12N5/0667Y10S514/866
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,101,570
App. No.
12/697,537
Granted
Aug 11, 2015
Kind
B1
Abstract

The anatomic and functional arrangement of the gastrointestinal tract suggests an important function of this organ is its ability to regulate the trafficking of metabolites as well as control the equilibrium between tolerance and immunity through gut-associated lymphoid tissue, the neuroendocrine network, and the intestinal epithelial barrier. Combining nucleated cells from various tissues and introducing them directly into the small intestine will have a positive effect on diabetes.

Claims (38)

1. A method to treat diabetes comprising:

implanting concentrated nucleated cells including stem cells from multiple source tissues directly into tissue of the duodenum to reset or repair the immune system or to reset or repair metabolite production in the duodenum, the concentrated nucleated cells being a heterogeneous population of cells and including cells from a bone marrow aspirate, a fat aspirate, cord blood, Wharton's Jelly, or afterbirth tissue.

2. The method according to claim 1 wherein the concentrated nucleated cells are implanted through an endoscopic procedure.

3. The method according to claim 1 wherein the concentrated nucleated cells are injected into the wall of the duodenum.

4. The method according to claim 1 wherein the concentrated nucleated cells include cells from a bone marrow aspirate.

5. The method according to claim 1 wherein the concentrated nucleated cells include cells from a fat aspirate.

6. The method according to claim 1 wherein the concentrated nucleated cells include cells from cord blood.

7. The method according to claim 1 wherein the concentrated nucleated cells include cells from Wharton's Jelly.

8. The method according to claim 1 wherein the concentrated nucleated cells are derived from autologous tissue.

9. The method according to claim 1 wherein the concentrated nucleated cells have been concentrated from source tissue by removing material that does not contain nucleated cells.

10. The method according to claim 1 further comprising delivering a portion of the concentrated nucleated cells into the venous or arterial system.

11. The method according to claim 1 further comprising:

sourcing nucleated cells from a patient; and

preparing the concentrated nucleated cells using the nucleated cells sourced from the patient, wherein the sourcing, preparing and implanting are performed in one point-of-care procedure.

12. The method according to claim 1 wherein the concentrated nucleated cells are implanted into the tissue of the duodenum of a patient diagnosed with type-1 diabetes during the progression of the destruction of the islets of the patient's pancreas.

13. The method according to claim 1 wherein the concentrated nucleated cells include subpopulations of nucleated cells from respective source tissues.

14. The method according to claim 1 further comprising:

in one point-of-care procedure,

preparing a combination of concentrated nucleated cells from multiple source tissues, the nucleated cells being derived from autologous tissue; and

implanting the combination directly into tissue of the duodenum of a patient diagnosed with type-1 diabetes during the progression of the destruction of the islets of the patient's pancreas.

15. A method to treat diabetes comprising:

obtaining tissue from a tissue source, the tissue source being bone marrow aspirate, cord blood, adipose tissue, Wharton's Jelly, or afterbirth tissue;

preparing concentrated nucleated cells including stem cells by removing a substantial amount of material other than nucleated cells from the tissue obtained, the concentrated nucleated cells being a heterogeneous population of cells; and

implanting the concentrated nucleated cells directly into tissue of the duodenum to reset or repair the immune system or to reset or repair metabolite production in the duodenum.

16. The method according to claim 15 wherein the concentrated nucleated cells include subpopulations of nucleated cells from the tissue source.

17. The method according to claim 15 performed in one point-of-care procedure,

wherein the tissue source is bone marrow aspirate from a patient,

wherein preparing the concentrated nucleated cells includes removing a large portion of non-nucleated red-blood cells and plasma from the bone marrow aspirate, and

wherein implanting the concentrated nucleated cells includes injecting the concentrated nucleated cells directly into the wall of the duodenum of the patient using an endoscope.

18. The method according to claim 17 wherein preparing the concentrated nucleated cells includes combining the concentrated nucleated cells from the bone marrow aspirate with nucleated cells sourced from placental tissue of a donor other than the patient.

19. The method according to claim 15 wherein the concentrated nucleated cells are injected into the wall of the duodenum of a patient diagnosed with type-1 diabetes during the progression of the destruction of the islets of the patient's pancreas.

20. The method according to claim 15 wherein the concentrated nucleated cells are implanted to reset or repair the interaction between the immune system and the insulin producing islets of the pancreas through repair of the duodenum.

21. The method according to claim 1 wherein the concentrated nucleated cells are implanted to reset or repair the interaction between the immune system and the insulin producing islets of the pancreas through repair of the duodenum.

22. A method to treat a patient diagnosed with type-1 diabetes, the method comprising:

preparing concentrated nucleated cells including stem cells from source tissue by removing material that does not contain nucleated cells from the source tissue and leaving a heterogeneous population of cells, the source tissue including a bone marrow aspirate from the patient, a fat aspirate from the patient, cord blood, or afterbirth tissue; and

implanting the concentrated nucleated cells into tissue of the patient's duodenum during the progression of the destruction of the islets of the patient's pancreas to reset or repair the patient's immune system.

23. The method according to claim 22 wherein preparing the concentrated nucleated cells includes combining the concentrated nucleated cells from multiple source tissues.

24. The method according to claim 22 wherein the concentrated nucleated cells are implanted to reset or repair the interaction between the immune system and the insulin producing islets of the pancreas through repair of the duodenum.

Assignments (4)
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Oct 31, 2023
From: CERVOS MEDICAL LLC
To: BERKSHIRE BANK
Reel/Frame 065414/0306 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2015
From: MCGILLICUDDY, ANDREW
To: ENDOCELLUTIONS, INC.
Reel/Frame 036215/0254 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 20, 2012
From: DUFFY, NEIL F.
To: ECW THERAPEUTICS, INC.
Reel/Frame 028079/0889 →
CHANGE OF NAME Recorded Apr 20, 2012
From: ECW THERAPEUTICS, INC.
To: ENDOCELLUTIONS, INC.
Reel/Frame 028081/0651 →
Continuity (1)
Provisional Application 61152417 · Feb 13, 2009